Introduction:
The pharmaceutical industry in China has been rapidly growing in recent years, with biologics playing a significant role in this expansion. As of 2026, China has become a key player in the biologics market, with several top manufacturers leading the way. The country’s focus on research and development, coupled with its large market size, has made it a hub for biologics production. According to industry reports, China’s biologics market is expected to continue its upward trajectory in the coming years, solidifying its position as a global leader in the industry.
Top 10 Biologics Manufacturers in China 2026:
1. Shanghai Henlius Biotech Inc.
Shanghai Henlius Biotech Inc. is a leading biopharmaceutical company in China, known for its innovative biologics products. With a production volume of over 100,000 units per year, the company holds a significant market share in the country. Their focus on research and development has led to the development of several successful biologics, making them a key player in the industry.
2. Fosun Pharma
Fosun Pharma is another major player in the Chinese biologics market, with an annual production volume of 80,000 units. The company has been expanding its biologics portfolio, with a focus on oncology and autoimmune diseases. Their commitment to innovation and quality has helped them gain a strong foothold in the market.
3. WuXi Biologics
WuXi Biologics is a leading contract development and manufacturing organization (CDMO) in China, specializing in biologics production. With state-of-the-art facilities and a production volume of over 150,000 units per year, the company has become a preferred partner for biologics companies worldwide. Their expertise in process development and manufacturing has set them apart in the industry.
4. BeiGene
BeiGene is a biopharmaceutical company in China, known for its focus on oncology and immuno-oncology. With a market share of 15% in the country, the company has been rapidly expanding its biologics pipeline. Their commitment to developing innovative therapies for cancer has positioned them as a key player in the market.
5. Innovent Biologics
Innovent Biologics is a biopharmaceutical company in China, specializing in the development of biologics for cancer and autoimmune diseases. With a production volume of 60,000 units per year, the company has gained recognition for its high-quality products. Their success in the market can be attributed to their strong research and development capabilities.
6. GenScript Biotech Corporation
GenScript Biotech Corporation is a biotechnology company in China, focusing on biologics research and development. With a market share of 10%, the company has been at the forefront of innovation in the industry. Their expertise in gene editing and protein engineering has led to the development of several successful biologics products.
7. CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company in China, known for its focus on oncology and immuno-oncology. With a production volume of 40,000 units per year, the company has been expanding its biologics portfolio rapidly. Their commitment to developing novel therapies for cancer has positioned them as a key player in the market.
8. Legend Biotech
Legend Biotech is a biopharmaceutical company in China, specializing in the development of cell therapy products. With a market share of 8%, the company has been at the forefront of innovation in the field. Their success in developing CAR-T cell therapies has set them apart in the industry.
9. 3SBio Inc.
3SBio Inc. is a biopharmaceutical company in China, known for its focus on biologics for nephrology and oncology. With a production volume of 30,000 units per year, the company has gained recognition for its high-quality products. Their commitment to developing therapies for chronic diseases has positioned them as a key player in the market.
10. Zai Lab
Zai Lab is a biopharmaceutical company in China, focusing on oncology and immunology. With a market share of 7%, the company has been rapidly expanding its biologics pipeline. Their success in developing novel therapies for cancer and autoimmune diseases has set them apart in the industry.
Insights:
The biologics market in China is poised for continued growth in the coming years, driven by factors such as increasing investment in research and development, growing demand for innovative therapies, and a strong regulatory environment. According to industry forecasts, the market is expected to reach a value of $10 billion by 2030, with biologics accounting for a significant portion of this growth. As China continues to establish itself as a global leader in the biologics industry, companies in the country will need to focus on innovation and quality to maintain their competitive edge. With a strong ecosystem of manufacturers, research institutions, and regulatory bodies, China is well-positioned to shape the future of biologics on a global scale.
Related Analysis: View Previous Industry Report
